GlassScriptPhysician profile
Benjamin James Newton
NPI 1093986697
$2,873.78
in general payments reported to CMS, 2019-2025
28 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $298 · 2021: $707 · 2022: $248 · 2023: $289 · 2024: $511 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $364.50 | 2021 | |
| Vertos Medical, INC. | $322.70 | 2021-2024 | Mild Device Kit |
| Depuy Synthes Sales INC. | $294.14 | 2019-2025 | Orthovisc, Monovisc |
| Pacira Therapeutics, INC. | $195.41 | 2019-2020 | |
| Foundation Fusion Solutions, LLC | $191.67 | 2022 | |
| Biotronik Nro, INC. | $165.30 | 2024-2025 | Prospera |
| Medtronic, INC. | $142.71 | 2021-2025 | Inceptiv, Intellis Adaptivestim, Synchromedii |
| Pacira Pharmaceuticals Incorporated | $127.72 | 2023-2025 | Zilretta, Iovera, Exparel |
| Merz North America, INC. | $123.91 | 2020 | |
| Medtronic USA, INC. | $115.26 | 2019-2020 | |
| Abbott Laboratories | $100.88 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $93.74 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $84.16 | 2021-2023 | Xtampza |
| Abbvie INC. | $83.07 | 2024-2025 | |
| Bioventus LLC | $59.39 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.77 | 2021-2024 | Relistor |
| Ferring Pharmaceuticals INC. | $51.06 | 2020 | |
| Azurity Pharmaceuticals, INC. | $45.29 | 2023 | Horizant |
| Si-Bone, INC. | $45.15 | 2020-2024 | |
| Averitas Pharma INC. | $42.38 | 2023 | Qutenza |
| Sanofi-Aventis U.S. LLC | $32.55 | 2021 | |
| Lundbeck LLC | $31.59 | 2024 | Vyepti |
| Relievant Medsystems, INC. | $28.97 | 2023 | Intracept |
| Curonix LLC | $17.56 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Electronic Waveform Lab, INC. | $16.83 | 2025 | |
| Scilex Pharmaceuticals INC. | $13.72 | 2025 | |
| Lilly USA, LLC | $13.53 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Newton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.